These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
441 related articles for article (PubMed ID: 16024335)
1. Effect of activated recombinant human factor 7 (Niastase) on laboratory testing of inhibitors of factors VIII and IX. Keeney M; Allan DS; Lohmann RC; Yee IH Lab Hematol; 2005; 11(2):118-23. PubMed ID: 16024335 [TBL] [Abstract][Full Text] [Related]
2. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone. Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255 [TBL] [Abstract][Full Text] [Related]
3. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Scharrer I Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179 [TBL] [Abstract][Full Text] [Related]
4. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion. Carr ME; Martin EJ; Kuhn JG; Seremetis SV Thromb Haemost; 2003 May; 89(5):803-11. PubMed ID: 12719776 [TBL] [Abstract][Full Text] [Related]
5. Inhibitor antibodies to factor VIII and factor IX: management. Lusher JM Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411 [TBL] [Abstract][Full Text] [Related]
6. Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI. Livnat T; Zivelin A; Martinowitz U; Salomon O; Seligsohn U J Thromb Haemost; 2006 Jan; 4(1):192-200. PubMed ID: 16409469 [TBL] [Abstract][Full Text] [Related]
7. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. He S; Blombäck M; Jacobsson Ekman G; Hedner U J Thromb Haemost; 2003 Jun; 1(6):1215-9. PubMed ID: 12871322 [TBL] [Abstract][Full Text] [Related]
8. Potential role of recombinant factor VIIa as a hemostatic agent. Hedner U; Erhardtsen E Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390 [TBL] [Abstract][Full Text] [Related]
9. The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa. Negrier C; Hay CR Semin Thromb Hemost; 2000; 26(4):407-12. PubMed ID: 11092216 [TBL] [Abstract][Full Text] [Related]
10. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors. Arkin S; Blei F; Fetten J; Foulke R; Gilchrist GS; Heisel MA; Key N; Kisker CT; Kitchen C; Shafer FE; Shah PC; Strickland D Blood Coagul Fibrinolysis; 2000 Apr; 11(3):255-9. PubMed ID: 10870806 [TBL] [Abstract][Full Text] [Related]
11. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries. Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484 [TBL] [Abstract][Full Text] [Related]
12. General haemostatic agents--fact or fiction? Hedner U Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145 [TBL] [Abstract][Full Text] [Related]
13. Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven. Johannessen M; Andreasen RB; Nordfang O Blood Coagul Fibrinolysis; 2000 Apr; 11(3):239-42. PubMed ID: 10870803 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the effect of plasma-derived and recombinant human FVIIa in vitro and in a rabbit model. Hedner U; Ljundberg J; Lund-Hansen T Blood Coagul Fibrinolysis; 1990 Jun; 1(2):145-51. PubMed ID: 2130926 [TBL] [Abstract][Full Text] [Related]
15. Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions. Aljamali MN; Kjalke M; Hedner U; Ezban M; Tranholm M Haemophilia; 2009 Nov; 15(6):1318-26. PubMed ID: 19659796 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice. Keshava S; Sundaram J; Rajulapati A; Pendurthi UR; Rao LV J Thromb Haemost; 2016 Mar; 14(3):546-50. PubMed ID: 26727350 [TBL] [Abstract][Full Text] [Related]
18. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors. Qi X; Zhao Y; Li K; Fan L; Hua B Blood Coagul Fibrinolysis; 2014 Oct; 25(7):754-60. PubMed ID: 24806320 [TBL] [Abstract][Full Text] [Related]
19. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160 [TBL] [Abstract][Full Text] [Related]
20. The in vitro analysis of the coagulation mechanism of activated factor VII using thrombelastogram. Kawaguchi C; Takahashi Y; Hanesaka Y; Yoshioka A Thromb Haemost; 2002 Nov; 88(5):768-72. PubMed ID: 12428092 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]